Schedule 13G ownership disclosure

Karyopharm Therapeutics Inc

Common Stock, $0.0001 par value · CUSIP: 48576U205

Event date: 2025-09-30

Filing-level shares
427,624.0
Percent of class
4.9%
  • JPMORGAN CHASE & CO.

    Shares: 427,624.0 · Class: 4.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000019617-25-001004
Form type
SCHEDULE 13G/A
Filer
JPMORGAN CHASE & CO
CIK
CIK 19617
Filed
Oct 17, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub